chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Chills; can't be touched, everything hurts from head to toe; looks very weak and can hardly walk; so sore; This spontaneous case was reported by a patient family member or friend and describes the occurrence of CHILLS (Chills), MYALGIA (can't be touched, everything hurts from head to toe), ASTHENIA (looks very weak and can hardly walk) and PAIN (so sore) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  The patient's past medical history included COVID-19 on 19-Mar-2021. Concomitant products included PRAVASTATIN and ERGOCALCIFEROL, RETINOL PALMITATE (VITAMINS A & D) for an unknown indication.   On 28-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In April 2021, the patient experienced CHILLS (Chills), MYALGIA (can't be touched, everything hurts from head to toe), ASTHENIA (looks very weak and can hardly walk) and PAIN (so sore). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 1 dosage form. At the time of the report, CHILLS (Chills), MYALGIA (can't be touched, everything hurts from head to toe), ASTHENIA (looks very weak and can hardly walk) and PAIN (so sore) outcome was unknown. Not Provided          The patient used Tylenol to treat his symptoms which followed the first dose.    This case was linked to MOD-2021-098377 (Patient Link).
Infant patient received adult bivalent dose of Moderna instead of infant bivalent; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Infant patient received adult bivalent dose of Moderna instead of infant bivalent) and NO ADVERSE EVENT (No adverse event) in an infant patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (Infant patient received adult bivalent dose of Moderna instead of infant bivalent) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Infant patient received adult bivalent dose of Moderna instead of infant bivalent) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Infant patient received adult bivalent dose of Moderna instead of infant bivalent).    No concomitant medications were reported.  On an unknown date, patient had taken Pfizer COVID-19 vaccine.  No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 01-Mar-2023: Non-significant follow-up appended
No adverse event; patient received the booster dose instead of the primary dose; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (patient received the booster dose instead of the primary dose) and NO ADVERSE EVENT (No adverse event) in a 34-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7168B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 03-Feb-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On 03-Feb-2023,  after starting , the patient experienced WRONG PRODUCT ADMINISTERED (patient received the booster dose instead of the primary dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (patient received the booster dose instead of the primary dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (patient received the booster dose instead of the primary dose).    No relevant concomitant medications were reported.  No treatment information was provided.
Blood sugar has stayed lower; This is a spontaneous report from a contactable consumer (patient himself).   A 66-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, lot number: eh9899) via an unspecified route of administration, administered in arm left on 03Jan2021 (at the age of 66-year-old) as dose number unknown, single for covid-19 immunisation.Medical history included diabetes, high blood pressure and high cholesterol. Concomitant medications included insulin taken for an unspecified indication and other medication (unspecified) was received within 2 weeks of vaccination. The patient had no known allergies to medications, food, or other products. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 09Jan2021,the patient reported that, two weeks after the shot, upon review of my glucose meter my endocrinologist reduced the amount of long-acting insulin by 25 percentage. Blood sugar had stayed lower, and the treatment short term insulin use was reduced also. The patient visited doctor or other healthcare professional office/clinic visit. On 09Jan2021, the patient lab data included blood sugar had stayed lower and short-term insulin use is reduced also. The outcome of the event was unknown.  Follow-up (12MAY2021): Follow-up attempts completed. No further information expected.  Follow-up attempts completed. No further information expected.
BRONCHITIS (FEVER AGAIN, SEVERE HEADACHE, CHILLS, SEVERE COUGH); DIZZINESS; COULD NOT WORK ONE WEEK AFTER SHOT; NAUSEA; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On an unspecified date, the patient experienced bronchitis (fever again, severe headache, chills, severe cough), dizziness, could not work one week after shot, and nausea. The action taken with covid-19 vaccine  was not applicable. The patient recovered from bronchitis (fever again, severe headache, chills, severe cough), dizziness, could not work one week after shot, and nausea. This report was non-serious.
administered expired dose; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 68-year-old male patient who received HAV (Havrix) (batch number 3a22r, expiry date 24th May 2022) for prophylaxis.   On 13th June 2022, the patient received Havrix. On 13th June 2022, unknown after receiving Havrix, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   Additional Information: GSK receipt date: 21-JUN-2022 Reporter's comment: The patient was administered expired doses of Havrix. The reporter was consented to follow up. Additional Supportive Information: The patient was administered expired doses of Havrix, which led expired vaccine used. This case is one of 3 linked cases, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022095705:Same reporter US-GLAXOSMITHKLINE-US2022095754:Same reporter
SHIVER UNCONTROLABLLY; FEVER; CRUSHING HEADACHE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. The patient's past medical history included fever, and sore throat, and other pre-existing medical conditions included the patient finished the last of a ten day antibiotic and the bacteria in "gut" were depleted. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: UNKNOWN) .5 ml, administered on 06-MAR-2021 11:30 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 06-MAR-2021, the subject experienced fever. On 06-MAR-2021, the subject experienced crushing headache. On 06-MAR-2021, the subject experienced shiver uncontrollably. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from shiver uncontrollably on 06-MAR-2021, and was recovering from fever, and crushing headache. This report was non-serious.
T+ 4 to 6 hours: mild fever, fatigue. T+ 1 days: mild fever continues, hot flashes begin, mostly at night interrupting sleep. T+ 2 days - 7 days: fever subsides, hot flashes increase in intensity significantly, continuing to interfere with sleep. Other possible androgenic symptoms begin to arise: change in body odor, sex drive, motivations, appetite. T+ 7 days till current: previous symptoms of days 2-7 continue, extremely gradual onset headache begins one night. Making sure to rule out hydration and electrolyte imbalance expecting headache to be gone in the morning after sleep, I found that it was only worse and that an interpolation of the two pain points from when I went to sleep and woke up would have created a almost imperceptibly gradual but linear increase between the two points. The headache was of a type I had never had before, located in the center of my head just barely dorsal to the spinal insertion. It felt deeper than any headache I had had before which usually occur in the frontal lobe/neocortex zone. I do not regularly suffer headaches getting maybe a couple per year. Once I recognized androgenic involvement and the headache were continuing I took myself to the ER where I was evaluated and despite presenting with continuous hypertension and the symptoms mentioned above, I could not get them to perform a estrogen test and they let me leave with hypertension without any investigation. I'm returning today to their urgent care facility to try again to get my estrogen levels checked. I had left a message on the phone line of VAERS prior to the original ER visit but had not heard back from anyone so I felt it was prudent to file a written report here.
Chills, Muscle aches, and swollen lymph node (palm size) under my left arm. Chills and muscle aches subsided after 24 hours, but lymph node is still tender and swollen to a size that is comparable to the palm of my hand.
Fever, chills, body aches, headache,  sinus drainage, soreness at vaccine sight.  All symptoms started 10 hours after receiving the vaccination.
Significant and widespread bruising on forearm of the R arm WITHOUT local reaction at site of injection on R; also with 3 bruises each >1 inch on contralateral (left) arm. no petechiae.
Fever muscle spasms Coughed blood Vaginal bleeding after no period over a year Headache
no adverse event; patient received a bivalent booster vaccine on January 8, 2023 instead of a first dose of the monovalent Primary Series; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (patient received a bivalent booster vaccine on January 8, 2023 instead of a first dose of the monovalent Primary Series) and NO ADVERSE EVENT (no adverse event) in a 9-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 074B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 08-Jan-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 08-Jan-2023, the patient experienced WRONG PRODUCT ADMINISTERED (patient received a bivalent booster vaccine on January 8, 2023 instead of a first dose of the monovalent Primary Series). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (patient received a bivalent booster vaccine on January 8, 2023 instead of a first dose of the monovalent Primary Series) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        The action taken with mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown) was unknown.   For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (patient received a bivalent booster vaccine on January 8, 2023 instead of a first dose of the monovalent Primary Series).    No Concomitant medication was reported. No treatment information was provided.
Covid vaccine on 1/30. On 2/7 in the evening: the injection site had a small 1-inch red spot. Then small red itchy bumps appeared on elbow of injection arm, on both thighs, behind knees, and scattered on hands, feet, chest, face, and back. Worst on thighs/legs. On the morning of 2/8, Urgent care prescribed prednisone and benadryl. Became increasingly itchy day 9-10 and started to bruise at the center of each red spot. Redness spread. Today is 2/10 and the redness/hives/itchiness appears to be subsiding. Followed up with primary care doctor today (2/10) and he confirmed treatment seems to be working. Doctors do not think it is related to the vaccine, but I have seen others online talking about full body rash/hives even a week to ten days after the shot, so I wanted to report just in case.  I also had a rapid COVID test done last night (2/9) and it was negative.
Pt reported that one week after vaccination he began having Left shoulder pain that has progressively gotten worse.  States has a firey feeling of pain that radiates throughout the arm and hand.  States sometimes can feel in the bone and shoulder area.  Reports has followed up with his PCP.
Headache, Myalgia, Fever, Has muscle pain right side of face and neck, has mild numbness on right side of face, no drooping. Narrative:
The person administering the vaccines did not add the diluent prior to injecting the patient with the vaccine. The patient was given an injection of the covid vaccine without diluent. Patient was spoken to, and no adverse reaction or events have been reported at this time.
arm is sore/arm still sore; Tired; unwell; overall weakness; achy; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (unwell), ASTHENIA (overall weakness), MYALGIA (achy), VACCINATION SITE PAIN (arm is sore/arm still sore) and FATIGUE (Tired) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 on 05-Nov-2020.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced MALAISE (unwell), ASTHENIA (overall weakness), MYALGIA (achy) and FATIGUE (Tired). On 15-Mar-2021, the patient experienced VACCINATION SITE PAIN (arm is sore/arm still sore). At the time of the report, MALAISE (unwell), ASTHENIA (overall weakness), MYALGIA (achy), VACCINATION SITE PAIN (arm is sore/arm still sore) and FATIGUE (Tired) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.  No treatment information provided.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jul-2021: Additional information received include no new information.
The same day as the vax, the pt developed a local reaction with skin involvement that lasted a week.
Had emergency gallbladder removed; After having Pfizer vacccine I developed so many lumps, and polyps./ Colon Polyp; After having Pfizer vacccine I developed so many lumps, and polyps.; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CHOLECYSTECTOMY (medically significant), outcome "unknown", described as "Had emergency gallbladder removed"; LARGE INTESTINE POLYP (intervention required, medically significant), outcome "unknown", described as "After having Pfizer vacccine I developed so many lumps, and polyps./ Colon Polyp"; MASS (non-serious), outcome "unknown", described as "After having Pfizer vacccine I developed so many lumps, and polyps.". Therapeutic measures were taken as a result of cholecystectomy, large intestine polyp.  Clinical course Action Taken was reported as remains live/visible. No more vaccines for patient. After having Pfizer vaccine developed so many lumps, and polyps. Had emergency gallbladder removed as well as colon polyps.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
I have been experiencing sporadic dizziness and light headedness before my 4th dose of Pfizer vaccine. However dizziness and lightheadedness was aggravated by each dose of the vaccine. I started monitoring my blood pressure because I thought it was low and my blood pressure this was normal. My dizzy spells increased in frequency and intensity. My Dr. has ruled out vertigo. The issue is ongoing.
About 24 hours from vaccine administration patient reported onset of chills fever body aches and nausea she took tylenol but still was extremely fatigued and curled into a ball. Symptoms resolved at 48 hour mark from vaccination. Patient also reported extremely sore arm.
I took my vaccination on 07/21/2022. On 10/06/2022 I woke up with a sore throat and I felt awful. The following day 10/07/2022 the pain was horrible. I tested COVID-19 Positive on that day. The doctor put me on Paxlovid.
Information has been received from a licensed practical nurse concerning an unknown number of patients of unknown age and gender. Medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patients were vaccinated with doses of ZOSTAVAX lot # M035694 (expiration date 07-NOV-2017) and M0347694 (expiration date 26-OCT-2017) administered subcutaneously for prophylaxis (dose not reported). The doses were stored at temperatures > 14 degrees Fahrenheit and < 46 degrees Fahrenheit (26.7 degrees Fahrenheit) for a total of 30 minutes as identified by a digital data logger. It was reported that there were no previous temperature excursions. No adverse effects were reported. There was no product quality complaint (PQC) involved. Lot number M0347694  is an invalid lot number for zoster vaccine live. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1701USA004169:
No additional adverse events reported; a dose of PROQUAD anda dose of VARlVAX were administered concomitantly to a 12 month old today; a dose of PROQUAD anda dose of VARlVAX were administered concomitantly to a 12 month old; This spontaneous report was received from a physician and refers to a 12-month-old patient of unknown gender. No information regarding the patient's medical history, drug reactions, allergies or concomitant therapies was provided.  On 27-APR-2021, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD), 0.5 ml (route of administration, lot # and expiration date were not provided) for prophylaxis. On the same day, the patient concomitantly received varicella virus vaccine live (oka/merck) (VARIVAX), 0.5 ml (route of administration, lot # and expiration date were not provided) for prophylaxis. No adverse events were reported.
Possible cellulitis; Probable aggressive immune reaction (Redness/swelling of left shoulder)
This spontaneous report was received from a 66 year old consumer regarding herself. The patient's current conditions included unspecified kidney disease, Sjogren's syndrome, chronic anemia and vacuities. The patient was allergic to AUGMENTIN, bacitracin, neomycin and PLAQUENIL. Information on concomitant therapies was not reported. On 18-SEP-2018, the patient was vaccinated with 2nd dose of pneumococcal vaccine, polyvalent (23-valent)(manufacture unknown)) in the upper left arm via intramuscular route for prevention of pneumococcal disease (dose, lot#, expiry date not reported). The patient received 1st dose of pneumococcal vaccine, polyvalent (23-valent)(manufacture unknown)) 4-5 years ago without any adverse reaction. On 18-SEP-2018, the patient underwent routine blood work due to pre-existing kidney disease. The patient's inflammation, cholesterol, creatinine, protein, and glomerular filtration rate (GFR) were all higher than previous results (also reported as "numbers were all worse"). On 23-SEP-2018, the patient experienced inflammation, glomerular filtration rate increased, protein total abnormal, blood creatinine increased and blood cholesterol increased. On 23-SEP-2018 the patient experienced swelling, itchiness, and "mild discomfort" at the injection site, as well as an area of redness at injection site "5 inches by 3 inches" in size. The patient called a nurse and sought advice. On an unknown date in October 2018 (also reported as 2 weeks later), the patient recovered from all the events without any treatment. Causality assessment was unknown. She also reported that she knew some other patient who had the same injection site reaction after receiving a dose of pneumococcal vaccine, polyvalent (23-valent)(manufacture unknown)) (MARRS# 1810USA006811). No product quality complaint associated with this report. This is one of the 2 reports from the same reporter. Sender's Comments: US-009507513-1810USA006811.
Confusion, Headache, Sedation,  Chills, no appetite Narrative: Per nursing report:"2nd Moderna vaccine on 1-25-21. C/o headache, chills, disorientation on Monday [1/25]. C/o feeling tired and sleepy. Called in today [1/27]. No appetite on Monday. States thought she was having side effects from aneurysm which she states has been monitoring x4 years now."
developed herpes zoster- shingles  on May 1, 2021 on left low back and buttocks.. Started on Valtrex when seen on May 3, 2021 but by May 11th  rash had progressed to multiple bilateral dermatomes including beneath both breasts, bilateral lower abdomen, bilateral groins and thighs and right arm.